Analysis of admissions for chronic obstructive pulmonary disease in Andalusia in 2000

被引:10
作者
Bodineau, JLLC
Guerra, JF
Blanquer, AL
López, EPM
Moreno, L
Gallardo, JJC
Jiménez, JMG
机构
[1] Hosp Costa del Sol, Unidad Neumol, Malaga, Spain
[2] Hosp Costa del Sol, Unidad Documentac Clin, Malaga, Spain
[3] Hosp Costa del Sol, Unidad Invest & Docencia, Malaga, Spain
来源
ARCHIVOS DE BRONCONEUMOLOGIA | 2002年 / 38卷 / 10期
关键词
chronic obstructive pulmonary disease epidemiology; cost;
D O I
10.1016/S0300-2896(02)75268-X
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
OBJECTIVE: To analyze the impact of admissions for chronic obstructive pulmonary disease (COPD) in Andalusia during 2000. METHODS: All patients with DRG codes 088 and 541, which would receive ICD-9 codes 491, 492, 493.2, 494 and 496 in the cause of admission field, were extracted from the Minimum Basic Data Set for Andalusia. We compiled descriptive statistics from these data, calculated the cost per day of hospitalization for our own hospital, and then extrapolated to estimate the cost for Andalusia. RESULTS: COPD exacerbations generated 10,386 admissions in 2000, leading to 117,011 days of hospitalization. Eighty-three percent of the patients were men and the mean age was 70 +/- 12 years. The average hospital stay was 11 +/- 10 days. Huelva was the province with the shortest hospital stay (9 days). Mortality was 6.7%. The minimum expenditure generated was E 27 million, not counting the cost of intensive care unit admissions. CONCLUSIONS: Admissions due to COPD have great impact on the Andalusian health care system. Further studies are needed to evaluate alternatives to hospitalization.
引用
收藏
页码:473 / 478
页数:6
相关论文
共 20 条
[1]  
Ballester F, 1999, Arch Bronconeumol, V35, P20
[2]   Medical progress: Chronic obstructive pulmonary disease. [J].
Barnes, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (04) :269-280
[3]  
CABRERA LM, 2001, NEUMOSUR, V13, P183
[4]  
*COM EXP SEPAR, 1995, EST MACR IMP SOC EC
[5]   Outcomes following acute exacerbation of severe chronic obstructive lung disease [J].
Connors, AF ;
Dawson, NV ;
Thomas, C ;
Harrell, FE ;
Desbiens, N ;
Fulkerson, WJ ;
Kussin, P ;
Bellamy, P ;
Goldman, L ;
Knaus, WA .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (04) :959-967
[6]  
DODGE R, 1986, AM REV RESPIR DIS, V133, P981
[7]  
FIGUERAS M, 1999, REV ESP FARMACOECONO, V2, P33
[8]   Economic burden of chronic obstructive pulmonary disease - Impact of new treatment options [J].
Friedman, M ;
Hilleman, DE .
PHARMACOECONOMICS, 2001, 19 (03) :245-254
[9]  
Hurd S, 2000, CHEST, V117, P1
[10]  
Miravitlles M, 1999, Arch Bronconeumol, V35, P152